HOME > Generic APIs at Crossroads
Generic APIs at Crossroads
-
Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
-
Generic APIs at Crossroads - 3: Gx Society Sets Up Committee for Discussions with Healthcare Providers and API Manufacturers
August 14, 2020
-
Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
August 13, 2020
-
Generic APIs at Crossroads - 1: Sawai Quality Chief Says Current Biz Structure Hampers Manufacturing Repatriation
July 29, 2020
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…